Recent Comments

Comment RSS

Glaucoma News and Research RSS Feed - Glaucoma News and Research

While there are many causes of glaucoma, most cases are associated with increased intraocular pressure. Loss of vision is usually characterized by a gradual reduction in peripheral vision, which can lead to a tunnel vision effect. Glaucoma affects approximately 100 million people globally and is one of the leading causes of blindness in the world today. An estimated three million Americans have this sight-threatening disease. Because it is painless and advances gradually, many people who have glaucoma or elevated IOP have not been diagnosed. If detected and treated early, vision can usually be preserved.

SoloHealth and Kroger stores team up to promote eye health awareness

19. November 2009 04:37
SoloHealth (www.solo-health.com), maker of EyeSite™ self-service vision testing and self-directed healthcare kiosks, has teamed with Atlanta area Kroger stores to promote eye health awareness and to encourage regular eye exams. [More]

Posted in: Healthcare News

Tags: , , ,

deCODE genetics files voluntary petition for relief under Chapter 11 of the United States Bankruptcy Code

17. November 2009 04:03
deCODE genetics, Inc. (Nasdaq: DCGN) today announced that it has filed a voluntary petition for relief under Chapter 11 of the United States Bankruptcy Code with the United States Bankruptcy Court for the District of Delaware to facilitate the sale of substantially all of its assets. deCODE is continuing to operate its business and manage its properties as a debtor-in-possession pursuant to Sections 1107 and 1108 of the Bankruptcy Code. [More]

Findings from post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse announced

16. November 2009 05:57
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced findings from a post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse-. In this study, Vyvanse demonstrated significant improvement in Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms as measured by the ADHD Rating Scale IV (ADHD-RS IV) and Connors' Parent Rating Scale-Revised Short (CPRS-RS) in children with ADHD aged 6 to 12 years. [More]

Shire announces findings from Phase 3 study data with Vyvanse

13. November 2009 04:41
Shire plc, the global specialty biopharmaceutical company, announced findings from a post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse®. In this study, Vyvanse demonstrated significant improvement in Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms as measured by the ADHD Rating Scale IV (ADHD-RS IV) and Connors' Parent Rating Scale-Revised Short (CPRS-RS) in children with ADHD aged 6 to 12 years. [More]

Positive results from Lexicon Pharmaceuticals' LX1031 Phase 2 study for IBS

13. November 2009 01:18
Lexicon Pharmaceuticals, Inc. announced today that the company's investigational new drug, LX1031, a tryptophan hydroxylase (TPH) inhibitor, demonstrated positive results in clinically important parameters for the treatment of non-constipating irritable bowel syndrome (IBS). [More]

Online patient support program for ADHD patients taking Vyvanse Capsules CII medication

11. November 2009 23:26
Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today announced the re-launch of FOCUS (http://www.vyvanseFOCUS.com), a free, online patient support program for adults taking once-daily Vyvanse® (lisdexamfetamine dimesylate) Capsules CII for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD), and the only online, branded personalized patient support program providing tips and tools for adults diagnosed with ADHD taking a prescription medication. [More]

ISTA Pharmaceuticals presents additional data from its Bepreve Phase 3 clinical studies

9. November 2009 08:18
ISTA Pharmaceuticals, Inc., today announced additional results from the Company's Bepreve(TM) (bepotastine besilate ophthalmic solution) 1.5% Phase 3 clinical studies. These results were presented in poster sessions at the 2009 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) in Miami Beach, FL. [More]

Posted in: Drug Trial News | Medical Condition News

Tags: , , , , , , , ,

Pediatrician recommends red reflex vision test for all newborns

7. November 2009 00:58
With the number of premature births and medically fragile infants now increasing in the U.S., a basic eye exam, including a red reflex test, should be given to all children shortly after birth, reports Angela Buffenn, M.D., M.P.H., Director of the Orbit and Eye Movement Institute at The Vision Center of Childrens Hospital Los Angeles. [More]

Posted in: Child Health News | Healthcare News

Tags: , , , ,

Gonorrhea medication may help fight cancer

6. November 2009 23:36
Drugs sometimes have beneficial side effects. A glaucoma treatment causes luscious eyelashes. A blood pressure drug also aids those with a rare genetic disease. The newest surprise discovered by researchers at the Johns Hopkins University School of Medicine is a gonorrhea medication that might help battle cancer. [More]

Inspire Pharmaceuticals reports net loss of $8.5 million for the third quarter ended September 30, 2009

5. November 2009 07:51
Inspire Pharmaceuticals, Inc. announced today financial results for the third quarter ended September 30, 2009, reporting a net loss of $8.5 million or ($0.12) per common share. [More]

IBN iCare to develop cutting-edge nanomaterials for ocular therapy

4. November 2009 04:45
Marking a significant bench to bedside research milestone in Singapore, the Institute of Bioengineering and Nanotechnology (IBN), the world's first bioengineering and nanotechnology research institute, and the National University Hospital (NUH) launched the IBN iCare and the NUH Eye Centre @ Biopolis at an official opening ceremony officiated by the Senior Minister of State for Trade and Industry and Education, S. Iswaran, at the Biopolis on Nov. 3, 2009. [More]

Multicenter study finds AMD patients can benefit from cataract surgery

2. November 2009 01:32
This month's Ophthalmology, the journal of the American Academy of Ophthalmology (Academy) reports on a national study that finds cataract surgery is likely to benefit patients with age-related macular degeneration (AMD) at all stages of the disease, on a clinical trial showing that the steroid triamcinolone may be effective in advanced diabetic macular edema (DME) patients when standard treatment fails, and on the public's use of two Academy-sponsored online eye health forums. [More]

Shire to present key data on ADHD treatments at national psychiatric meeting

31. October 2009 05:07
Shire plc, the global specialty biopharmaceutical company, announced today that it will present key scientific data on its Attention-Deficit/Hyperactivity Disorder (ADHD) treatments, INTUNIV- (guanfacine) Extended Release Tablets, Vyvanse- (lisdexamfetamine dimesylate) Capsules CII, and Daytrana- (methylphenidate transdermal system) CII, at a national meeting of psychiatrists to be held October 27 - November 1 in Honolulu. [More]

Shire announces Phase IIIb study results of Daytrana

31. October 2009 04:01
Shire plc, the global specialty biopharmaceutical company, today announced findings at a major medical meeting from a Phase IIIb study of the tolerability and effectiveness of Daytrana® (methylphenidate transdermal system) in adolescents aged 13 to 17 years diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD). [More]

Shire's ADHD treatment data to be presented at the Honolulu psychiatric meeting

30. October 2009 06:01
Shire plc, the global specialty biopharmaceutical company, announced today that it will present key scientific data on its Attention-Deficit/Hyperactivity Disorder (ADHD) treatments, INTUNIV(TM) (guanfacine) Extended Release Tablets, Vyvanse®( ) (lisdexamfetamine dimesylate) Capsules CII, and Daytrana®( ) (methylphenidate transdermal system) CII, at a national meeting of psychiatrists to be held October 27 - November 1 in Honolulu. [More]
News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.